Lennox-Gastaut Syndrome (LGS) Therapeutics

Dec. 1, 2011 - PRLog -- GlobalData valued the global Lennox-Gastaut Syndrome (LGS) therapeutics market at $86.44m in 2010, and it is forecast to grow at a compound annual growth rate (CAGR) of 13.45% during 2010-2018 to reach $237.21m by 2018. The patents for LGS of leading second generation antiepileptic drugs (AEDs) such as Lamictal (lamotrigine), Topamax (topiramate) and Felbatol (felbamate) have expired during the historical period 2005-2010, however the introduction of Onfi (clobazam) in the US in 2011 is predicted to drive double-digit growth for the global LGS therapeutics market through 2018. According to current estimates, Onfi will be available in pharmacies in the US in January 2012. Importantly, the US market accounts for more than 90% of the global market. The future LGS therapeutics market will be characterized by strong generic competition. The introduction of Banzel/Inovelon (rufinamide) in the US and EU, the patent expiry of drugs such as Lamictal, Topamax and Felbatol across the seven major markets accounted for a CAGR of 3.91% during the historical period 2005-2010.

The LGS therapeutics market has significant unmet needs. Drugs such Lamictal, Topamax and Felbatol and Banzel/Inovelon are commonly prescribed for the treatment of LGS. However, these currently available AEDs only focus on improving the patient’s Quality of Life (QoL) and do not target the underlying cause of the disease. The currently available treatments do not provide complete alleviation from seizures and mental regression. This suggests that there is still scope for new market entrants offering superior efficacy and safety and possibly offering a complete cure for LGS.

The etiology and pathophysiology of LGS is complex as it involves different causative factors as well as different mechanism pathways. A complex pathophysiology represents a challenging clinical development environment and may not be conducive to the development of a single drug, which can block multiple pathophysiologic pathways and ultimately present a cure for the disease.

For Sample Pages, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/RequestSamplePages....

Limited understanding about the etiology and pathophysiology of LGS makes it reasonably complicated for the pharmaceutical companies to focus on newer drug targets. This establishes the presence of a limited number of large multinationals within the LGS therapeutics market. In the current LGS therapeutics market, multinationals such as Eisai, Johnson & Johnson (J&J), and GlaxosmithKline (GSK) have significant presence. Moreover, the current LGS therapeutics pipeline consists of only one molecule. This suggests that the drug development for LGS is challenging.

GlobalData estimates that the patent expiry of Lamictal, Topamax and Felbatol will result in strong generic competition through to 2018. However, Lundbeck is likely to capture substantial market share through Onfi (launched in the US in 2011). It is estimated that Onfi would drive the future LGS therapeutics market due to its superior efficacy in comparison with the currently available treatment options such as Banzel/ Inovelon, Lamictal, Topamax and Felbatol

GlobalData, the industry analysis specialist, has released its new report, “Lennox Gastaut Syndrome (LGS) Therapeutics-Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global LGS therapeutics market, identifying the key trends shaping and driving the global LGS market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global LGS sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

For further details, please click or add the below link to your browser:
http://www.globaldata.com/reportstore/Report.aspx?ID=Lenn...

Visit our report store: http://www.globaldata.com/reportstore

For more details contact:
pressreleases@globaldata.com
           
North America:    +1 646 395 5477
Europe:        +44 207 753 4299
           +44 1204 543 533
Asia Pacific:       +91 40 6616 6782

# # #

GlobalData is a global market intelligence services company providing information research and analysis products and services.